Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.

导出 OA

翻译打印收藏纠错

作者： Richard L,Tower ^[1] ; Tamekia L,Jones ; Bruce M,Camitta ; Barbara L,Asselin ; Beverly A,Bell ; Allen,Chauvenet ; Meenakshi,Devidas ; Edward C,Halperin ; Jeanette,Pullen ; Jonathan J,Shuster ; Naomi,Winick ; Joanne,Kurtzberg

作者单位： *MACC Fund Center for Cancer and Blood Disorders, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI †Department of Biostatistics, Colleges of Medicine and Public Health and Health Professions ††Department of Health Outcomes and Policy and Clinical and Translational Science Institute, College of Medicine, University of Florida ¶Children's Oncology Group, Department of Biostatistics, Gainesville, FL ‡Department of Pediatrics, Golisano Children's Hospital at University of Rochester Medical Center, Rochester #New York Medical College, Valhalla, NY §Department of Pediatrics, Georgia Health Sciences University, Augusta, GA ∥Department of Pediatrics, Charleston Division, West Virginia University, Charleston, WV **Department of Pediatric Hematology/Oncology, University of Mississippi Medical Center, Jackson, MS ‡‡Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX §§Pediatric Blood and Marrow Transplant Program, Duke University Medical Center, Durham, NC. ^[1]